In a previous study (22), which included both progressive and non-progressive BC patients, we showed that none of the non-progressive patients harboring ATM and TERT mutations in their primary tumors, present these mutations in their cfDNA during their follow-up after RC. This evidence concerns the gene TERT and breast cancer.